Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: A substudy of TALENT

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Falcone, Colomba ^a,b   Buzzi, Maria Paola ^a,b   Bozzini, Sara ^a   Boiocchi, Chiara ^a   D'Angelo, Angela ^a   Schirinzi, Sandra ^b   Esposito, Ciro ^a   Torreggiani, Massimo ^a   Choi, Jasmine ^c   Ochan Kilama, Michael ^c   Mancia, Giuseppe ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b University and Research Hospital   (Italy)

^c Dompè Pharmaceutical S p A   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CREATININE; NIFEDIPINE; TELMISARTAN; ADVANCED GLYCATION END PRODUCT; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LABORATORY TEST; LONG TERM CARE; MALE; METABOLIC DISORDER; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ADOLESCENT; ALBUMINURIA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DRUG COMBINATIONS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; YOUNG ADULT;

EID: 84858114914     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/874149     Document Type: Article

References (38)

1. Ross R., Atherosclerosis-an inflammatory disease The New England Journal of Medicine 1999 340 115 126
2. Chae C. U., Lee R. T., Rifai N., Ridker P. M., Blood pressure and inflammation in apparently healthy men Hypertension 2001 38 3 399 403 (Pubitemid 34225673)
3. Parissis J. T., Korovesis S., Giazitzoglou E., Kalivas P., Katritsis D., Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1 International Journal of Cardiology 2002 83 1 13 21 (Pubitemid 34311872)
4. Pockley A. G., De Faire U., Kiessling R., Lemne C., Thulin T., Frostegrd J., Circulating heat shock protein and heat shock protein antibody levels in established hypertension Journal of Hypertension 2002 20 9 1815 1820
5. Perry H. M. Jr., Miller J. P., Fornoff J. R., Baty J. D., Sambhi M. P., Rutan G., Moskowitz D. W., Carmody S. E., Early predictors of 15-year end-stage renal disease in hypertensive patients Hypertension 1995 25 4 587 594
6. Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J., Blood pressure and end-stage renal disease in men The New England Journal of Medicine 1996 334 1 13 18 (Pubitemid 26012498)
7. Dreke T. B., Massy Z. A., Atherosclerosis in CKD: differences from the general population Nature Reviews Nephrology 2010 6 723 735
8. Di Napoli M., Papa F., Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke Stroke 2003 34 12 2922 2929 (Pubitemid 37517770)
9. Mizuno Y., Jacob R. F., Mason R. P., Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease American Journal of Hypertension 2008 21 10 1076 1085
10. Ruiz-Ortega M., Lorenzo O., Ruperez M., Egido J., ACE inhibitors and AT1 receptor antagonistsbeyond the haemodynamic effect Nephrology Dialysis Transplantation 2000 15 5 561 565 (Pubitemid 30242966)
11. Forbes J. M., Thorpe S. R., Thallas-Bonke V., Pete J., Thomas M. C., Deemer E. R., Bassal S., El-Osta A., Long D. M., Panagiotopoulos S., Jerums G., Osicka T. M., Cooper M. E., Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy Journal of the American Society of Nephrology 2005 16 8 2363 2372 (Pubitemid 41725054)
12. Brett J., Schmidt A. M., Shi Du Yan, Yu Shan Zou, Weidman E., Pinsky D., Nowygrod R., Neeper M., Przysiecki C., Shaw A., Migheli A., Stern D., Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues American Journal of Pathology 1993 143 6 1699 1712 (Pubitemid 24058273)
13. Schmidt A. M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., Wang F., Pan Y. C. E., Tsang T. C., Stern D., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface Journal of Biological Chemistry 1992 267 21 14987 14997
14. Basta G., Schmidt A. M., De Caterina R., Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovascular Research 2004 63 4 582 592 (Pubitemid 39078671)
15. Lindsey J. B., Cipollone F., Abdullah S. M., McGuire D. K., Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research 2009 6 1 7 14
16. Malherbe P., Richards J. G., Gaillard H., Thompson A., Diener C., Schuler A., Huber G., cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein Molecular Brain Research 1999 71 2 159 170 (Pubitemid 29492960)
17. Falcone C., Emanuele E., D'Angelo A., Buzzi M. P., Belvito C., Cuccia M., Geroldi D., Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 5 1032 1037 (Pubitemid 40627851)
18. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., Emoto M., Shoji T., Tamei H., Matsuki H., Sakurai S., Yamamoto Y., Yonekura H., Watanabe T., Yamamoto H., Nishizawa Y., Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 12 2587 2593 (Pubitemid 43732283)
19. Basta G., Sironi A. M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., Gastaldelli A., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein Journal of Clinical Endocrinology and Metabolism 2006 91 11 4628 4634 (Pubitemid 44833448)
20. Humpert P. M., Kopf S., Djuric Z., Wendt T., Morcos M., Nawroth P. P., Bierhaus A., Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes Diabetes Care 2006 29 5 1111 1113 (Pubitemid 44115254)
21. Lanati N., Emanuele E., Brondino N., Geroldi D., Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation Current Vascular Pharmacology 2010 8 1 86 92
22. Mancia G., Parati G., Bilo G., Choi J., Kilama M. O., Ruilope L. M., Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: The TALENT Study Journal of Hypertension 2011 29 3 600 609
23. Levey A. S., Berg R. L., Gassman J. J., Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group Kidney International 1989 27 S73 S80
24. Atlas of chronic kidney disease and end stage renal disease in the United States. United States Renal Data System [online]. 2010, http://www.usrds.org/
25. Anavekar N. S., McMurray J. J. V., Velazquez E. J., Solomon S. D., Kober L., Rouleau J. L., White H. D., Nordlander R., Maggioni A., Dickstein K., Zelenkofske S., Leimberger J. D., Califf R. M., Pfeffer M. A., Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction The New England Journal of Medicine 2004 351 13 1285 1295 (Pubitemid 39258422)
26. Thomas M. C., Soderlund J., Lehto M., Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes Diabetologia 2011 54 10 2669 2677
27. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., Inoue H., Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-, activation Journal of International Medical Research 2007 35 4 482 489 (Pubitemid 47261110)
28. Yamagishi S. I., Nakamura K., Matsui T., Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine Current Medicinal Chemistry 2008 15 2 172 177 (Pubitemid 351234620)
29. Matsui T., Yamagishi S. I., Takeuchi M., Ueda S., Fukami K., Okuda S., Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation Biochemical and Biophysical Research Communications 2009 385 2 269 272
30. Park L., Raman K. G., Lee K. J., Lu Y., Ferran L. J., Choe W. S., Stern D., Schmidt A. M., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts Nature Medicine 1998 4 9 1025 1031 (Pubitemid 28417334)
31. Basi S., Lewis J. B., Microalbuminuria as a target to improve cardiovascular and renal outcomes American Journal of Kidney Diseases 2006 47 6 927 946 (Pubitemid 43767323)
32. Yu J. Y., An X. F., Liu J. S., Ten S. C., Wang X., Zhao Y., Huang S., Gu W. J., Gao F., Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage Diabetes Research and Clinical Practice 2010 87 2 157 160
33. Kakov K., Kalousov M., Hertlov M., Krusov D., Olovsk J., Zima T., Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene Archives of Physiology and Biochemistry 2008 114 2 111 119 (Pubitemid 351892711)
34. Basta G., Leonardis D., Mallamaci F., Cutrupi S., Pizzini P., Gaetano L., Tripepi R., Tripepi G., De Caterina R., Zoccali C., Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease Kidney International 2010 77 3 225 231
35. Ogihara T., Nakao K., Fukui T., Fukiyama K., Ueshima K., Oba K., Sato T., Saruta T., Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 2008 51 2 393 398 (Pubitemid 351159955)
36. Saruta T., Hayashi K., Ogihara T., Nakao K., Fukui T., Fukiyama K., Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: Subanalysis of the CASE-J Study Hypertension Research 2009 32 6 505 512
37. Matsuoka H., STONE study and INSIGHT study: efficacy of nifedipine in the prevention of cardiovascular disease in hypertensive patients Drugs 2006 66 13 15
38. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Koide H., Ueda Y., Takeuchi M., Yamagishi S.-I., Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage i or II chronic kidney disease Clinical Cardiology 2011 34 6 372 377